ALK and non-small cell lung carcinoma: ,22 Similarly, ceritinib has an ORR of 39% to 43% (by investigator assessment), median duration of response of 6.9 to 9.7 months, median PFS (by investigator assessment) of 5.7 to 6.7 months, and median overall survival of 14.9 months in patients with ALK+ NSCLC previously treated with chemotherapy and crizotinib6,23; among patients with measurable brain metastases, the intracranial ORR was 35%, with median duration of intracranial response of 6.9 months.6